Search our Innovation Portfolio

qXR, a class II CE approved medical device, detects and localises 20+ abnormalities on a CXR including the presence of lung nodules. qXR is intended to support consultant radiologists and reporting radiographers in clinical decision making. It is an automated chest x-ray AI algorithm to improve efficiency, accuracy and turnaround time (TAT) in reporting CXRs. QXR is deployed in more than 30+ countries for multiple disease applications including Tuberculosis, COVID-19 and Lung cancer. With two US patents for the product and several validation studies published in leading journals like The Lancet, qXR has proven to be accurately identifying the abnormalities in the lung, in a few minutes.

Pancreatic and bile duct cancer have the worst outlook of any cancer but the slowest diagnosis given their location deep in the body. The current pathway relies on invasive biopsies to diagnose these cancers. This pathway is slow, with some patients having repeated procedures to get a diagnosis, often resulting in delays to patients starting treatment.

A liquid biopsy is a non-invasive blood test which can be used to detect tumour DNA in the blood of patients with suspected pancreatic and biliary tract cancers. We will add liquid biopsies into the current diagnostic pathway, to cut through major bottlenecks and enable patients to access treatment earlier.

This implementation pilot study of whole body-MRI in patients with Li-Fraumeni syndrome, will explore the feasibility and added value of addition of this routinely available, non-ionising radiation scan to standard of care for LFS.

During the study, patient will undergo an annual WB-MRI, with the expectation that some will have early-stage, curable cancers identified. This study will present a proof of principle of the use of WB-MRI screening in specific patient cohorts and provide an exemplar of ‘targeted screening’. If successful, it would enable us to establish WB-MRI as a standard of care in adult LFS through further cost-effectiveness assessment providing valuable evidence of the importance of this intervention to NHS Commissioning bodies.